{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:43:06Z","timestamp":1779298986921,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T00:00:00Z","timestamp":1512172800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40264-017-0622-2","type":"journal-article","created":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T01:20:06Z","timestamp":1512177606000},"page":"357-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors"],"prefix":"10.1007","volume":"41","author":[{"given":"Abril","family":"Verden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mo","family":"Dimbil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Overstreet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith B.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,2]]},"reference":[{"key":"622_CR1","unstructured":"Eli Lilly and Company. Lilly and Incyte provide update on baricitinib. 2017. \n                        https:\/\/investor.lilly.com\/releasedetail.cfm?releaseid=1034247\n                        \n                    . Accessed 25 Sep 2017."},{"key":"622_CR2","unstructured":"European Medicines Agency. Committee for medicinal products for human use (CHMP). Draft agenda for the meeting on 17\u201320 July 2017. 2017. \n                        http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Agenda\/2017\/07\/WC500231582.pdf\n                        \n                    . Accessed 25 Sep 2017."},{"issue":"6","key":"622_CR3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s40264-016-0409-x","volume":"39","author":"KB Hoffman","year":"2016","unstructured":"Hoffman KB, Dimbil M, Tatonetti NP, Kyle RF. A pharmacovigilance signaling system based on FDA regulatory action and post-marketing adverse event reports. Drug Saf. 2016;39(6):561\u201375.","journal-title":"Drug Saf."},{"issue":"6","key":"622_CR4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"1","key":"622_CR5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2125.2005.02510.x","volume":"61","author":"JG Levine","year":"2006","unstructured":"Levine JG, Tonning JM, Szarfman A. Reply: The evaluation of data mining methods for the simultaneous and systematic detection of safety signals in large databases: lessons to be learned. Br J Clin Pharmacol. 2006;61(1):105\u201313.","journal-title":"Br J Clin Pharmacol."},{"key":"622_CR6","unstructured":"Advera Health Analytics. Drug\/AE analysis. 2017. \n                        https:\/\/info.adverahealth.com\/drug-safety-reference-xeljanz-pulmonary-thrombosis\n                        \n                    . Accessed 25 Sep 2017."},{"key":"622_CR7","unstructured":"Advera Health Analytics. Drug\/AE analysis. 2017. \n                        https:\/\/info.adverahealth.com\/drug-safety-reference-jakafi-pulmonary-thrombosis\n                        \n                    . Accessed 25 Sep 2017."},{"key":"622_CR8","unstructured":"Advera Health Analytics. Drug\/AE analysis. 2017. \n                        https:\/\/info.adverahealth.com\/drug-safety-reference-jakafi-portal-vein-thrombosis\n                        \n                    . Accessed 25 Sep 2017."},{"issue":"7309","key":"622_CR9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/bmj.323.7309.359","volume":"323","author":"F Charatan","year":"2001","unstructured":"Charatan F. Bayer decides to withdraw cholesterol lowering drug. BMJ. 2001;323(7309):359.","journal-title":"BMJ."},{"key":"622_CR10","unstructured":"FDA. Questions and answers: FDA recommends against the continued use of Meridia (sibutramine). 2010. \n                        https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm228747.htm\n                        \n                    . Accessed 5 Nov 2017."},{"key":"622_CR11","unstructured":"FDA. FDA public health advisory: safety of Vioxx. 2004. \n                        https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm106274.htm\n                        \n                    . Accessed 5 Nov 2017."},{"key":"622_CR12","unstructured":"FDA. FDA Adverse Events Reporting System (FAERS) public dashboard. 2017. \n                        https:\/\/fis.fda.gov\/sense\/app\/777e9f4d-0cf8-448e-8068-f564c31baa25\/sheet\/7a47a261-d58b-4203-a8aa-6d3021737452\/state\/analysis\n                        \n                    . Accessed 5 Nov 2017."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0622-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0622-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0622-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T12:57:11Z","timestamp":1522414631000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0622-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,2]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["622"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0622-2","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,2]]}}}